RTW INVESTMENTS, LP
Institutional investor · Portfolio as of Q3 2023
Top Holdings67 positions
Stock | Shares | Value | Weight | Avg Buy | Est. P&L | Held | Conviction |
|---|---|---|---|---|---|---|---|
ROCKET PHARMACEUTICALS INC | 17.7M | $362.4M | 7.6% | $18.79 | +9.03% | 19 qtrssince 2019-Q1 | Unchanged 0 |
IMMUNOCORE HLDGS PLC | 6.1M | $316.4M | 6.7% | $43.05 | +20.55% | 11 qtrssince 2021-Q1 | Increased 61 |
AXSOME THERAPEUTICS INC | 4.5M | $313.8M | 6.6% | $61.42 | +13.79% | 19 qtrssince 2019-Q1 | Increased 63 |
ALNYLAM PHARMACEUTICALS INC | 1.7M | $298.1M | 6.3% | $94.58 | +87.25% | 19 qtrssince 2019-Q1 | Unchanged 0 |
MIRATI THERAPEUTICS INC | 6.8M | $294.8M | 6.2% | — | — | 19 qtrssince 2019-Q1 | Increased 83 |
ARGENX SE - ADR | 507,195 | $249.4M | 5.3% | $338.40 | +45.28% | 19 qtrssince 2019-Q1 | Increased 63 |
ACADIA Pharmaceuticals Inc. | 11.6M | $241.3M | 5.1% | $18.32 | +13.78% | 6 qtrssince 2022-Q2 | Increased 70 |
BRUKER CORP | 3.4M | $210.7M | 4.4% | $72.62 | -14.96% | 3 qtrssince 2023-Q1 | Increased 64 |
Ultragenyx Pharmaceutical, Inc. | 5.4M | $192.7M | 4.1% | $54.54 | -34.64% | 8 qtrssince 2021-Q4 | Unchanged 0 |
PENUMBRA INC | 673,371 | $162.9M | 3.4% | $262.94 | -8.00% | 9 qtrssince 2021-Q3 | Unchanged 0 |
PTC THERAPEUTICS INC | 7.2M | $162.1M | 3.4% | $43.80 | -48.84% | 19 qtrssince 2019-Q1 | Unchanged 0 |
THERMO FISHER SCIENTIFIC INC | 290,334 | $147M | 3.1% | $570.15 | -11.83% | 9 qtrssince 2021-Q3 | Unchanged 0 |
MASIMO CORP | 1.5M | $131.7M | 2.8% | $174.28 | -49.69% | 19 qtrssince 2019-Q1 | Unchanged 0 |
ESTABLISHMENT LABS HLDGS INC | 2.5M | $122.4M | 2.6% | $24.97 | +96.52% | 19 qtrssince 2019-Q1 | Unchanged 0 |
NATERA INC | 2.7M | $117.3M | 2.5% | $42.12 | +5.07% | 17 qtrssince 2019-Q3 | Increased 52 |
VERICEL CORP | 3.3M | $110.3M | 2.3% | $17.89 | +87.41% | 19 qtrssince 2019-Q1 | Unchanged 0 |
SAGE THERAPEUTICS INC | 5.1M | $106M | 2.2% | — | — | 1 qtr | New 78 |
Celldex Therapeutics, Inc. | 3.5M | $95.3M | 2.0% | $16.46 | +67.20% | 14 qtrssince 2020-Q2 | Unchanged 0 |
PROTAGONIST THERAPEUTICS INC | 5.4M | $90.3M | 1.9% | $22.38 | -25.48% | 17 qtrssince 2019-Q3 | Unchanged 0 |
CYTOKINETICS INC | 2.6M | $75.8M | 1.6% | $27.00 | +9.10% | 13 qtrssince 2020-Q3 | Unchanged 0 |
RTW INVESTMENTS, LP manages $4.7B across 67 positions as of Q3 2023. Top holdings: RCKT (7.6%), IMCR (6.7%), AXSM (6.6%). Fund DNA: Balanced Allocator. HoldingsIntel Rating: 3/5.0.
Active quarter - 10 new positions, 5 exits, 16 increased. Top move: MRTX (INCREASED, conviction 83). Portfolio: $4.7B across 67 positions.
Top holdings by portfolio weight
Portfolio allocation by GICS sector
Behavioral investing profile
Position Outcomes
Best and worst performing positions by estimated return
Top Winners
Top Losers
Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.
Similar Funds
Funds with similar investing DNA
Explore More
Accumulation Streaks
Positions with 2+ consecutive quarters of increases - persistent directional conviction.
Continue exploring
Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer